Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187822 · ClinicalTrials.gov registry record · Phase 1
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02187822 is a Phase 1 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 15 participants.
The verdict
NCT02187822, a Phase 1 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in people with brain metastases from their cancer.
Interventions
- DRUG TPI 287
- PROCEDURE Fractionated Stereotactic Radiotherapy (FSRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-10-09 |
| Est. Completion | 2018-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02187822
The ClinicalTrials.gov registry entry for NCT02187822 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TPI 287 is the first listed.
NCT02187822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02187822 about?
NCT02187822 is a clinical study titled "Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases". The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in people with brain metastases from their cancer.
What is the current status of trial NCT02187822?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-10-09. Estimated completion is 2018-03-31.
What interventions are being tested in trial NCT02187822?
The interventions under investigation include: TPI 287 (DRUG), Fractionated Stereotactic Radiotherapy (FSRT) (PROCEDURE).
Who is sponsoring clinical trial NCT02187822?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.